A new Novartis AG drug to treat heart failure should cost 17 percent less than its list price of $4,560 per year to keep health costs in line with growth in the overall U.S. economy, according to the nonprofit ICER.
In a draft report released on Friday, the Boston-based Institute for Clinical and Economic Review set its "value-based" price for Entresto at $3,799 annually. The independent ICER evaluates clinical and cost effectiveness of new medicines.
13:12 Putin Wants to Work With Trump as Equals to Restore Relations12
06:52 France's Carrefour eyes second-quarter 2017 4.5 billion euros IPO of Carmila arm: report15
10:45 OECD sees resurgent US growth boosting global economy11
16:31 Crowds Pick Up Slightly on Black Friday as Online Sales Surge11